Xuerui Li

机构：Nankai University · ORCID：0000-0003-2538-4146

发表论文 90 篇 · 总被引 1609 次 · h-index 23

代表论文

• Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial (2023 · Journal for ImmunoTherapy of Cancer · 被引 131)
• Conversion therapy with an immune checkpoint inhibitor and an antiangiogenic drug for advanced hepatocellular carcinoma: A review (2022 · BioScience Trends · 被引 35)
• Association of life‐course traumatic brain injury with dementia risk: A nationwide twin study (2022 · Alzheimer s & Dementia · 被引 22)
• Comparison of survival benefit between salvage surgery after conversion therapy versus surgery alone for hepatocellular carcinoma with portal vein tumor thrombosis: a propensity score analysis (2023 · HPB · 被引 21)
• Landscape of the Peripheral Immune Response Induced by Intraoperative Radiotherapy Combined with Surgery in Early Breast Cancer Patients (2024 · Advanced Science · 被引 18)
• High lifelong cognitive reserve prolongs disability‐free survival: The role of cognitive function (2022 · Alzheimer s & Dementia · 被引 16)